Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imre study

This article was originally published in The Gray Sheet

Executive Summary

Published in the March issue of Cancer, the journal of the American Cancer Society, finds that 25 of 55 patients with chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome responded to treatment with the Imre Prosorba immunoadsorption column. Of the patients who responded, 61% had an "estimated one-year survival rate." Only 22% of patients who did not respond to the Prosorba therapy demonstrated a one-year survival rate. In the study, Harry Snyder, PhD, Imre Corporation, et al. find "protein A immunoadsorption...an effective and safe treatment for cancer chemotherapy-associated TTP/HUS".
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel